Biogen Idec topped Q4 estimates and guided 2015 above expectations Thursday after fellow big-cap biotech Alexion Pharmaceuticals also beat but guided light. But both stocks rallied strongly. After the close, Biogen (BIIB) said that earnings minus one-time items rose 74% to $4.09 a share, the third straight quarter of accelerating year-over-year growth. It beat the analyst consensus by 31 cents, according to Thomson Reuters. Sales
Shares of biotechs moved lower in afternoon trading Wednesday — along with the broader markets — even though Amgen (AMGN) topped quarterly earnings and revenue views after Tuesday’s close and analysts expect strong results from Biogen Idec (BIIB) and Celgene (CELG) when they report on Thursday. Wednesday’s dip comes during an otherwise robust recent run for IBD’s Medical-Biomed/Biotech group, which ranks No. 1 out of 197 industries tracked. The
Earnings season is really shifting into high gear this week. With dozens of major companies reporting, it’s important to focus on the very best. Let’s take a look at some of the most notable IBD 50 stocks with upcoming earnings. Apple (AAPL) reports after the close on Tuesday, and its results are sure to be boosted by its iPhone 6 lineup. Up next we have Biogen (BIIB), which reports before the open on Wednesday. The biotech recently added